Latest news
Canada: An overview of the healthcare system

In this fact file, Nasos Kipentzogolou, Senior Analyst at Lightning Health, takes a look at the healthcare system in Canada: a decentralised healthcare system

The growing field of psychedelic research in psychiatric diseases and mental health

Nancy Cross, Senior Analyst at Lightning Health, provides a brief background on psychedelics and their use in medicine and clinical research

China: Draft policy that could impact the EDL, paediatrics and rare diseases

Xin Zhao, Senior Consultant at Lightning Health, maps out the impact these potential new regulations could have

Germany: Planned reforms to hospitals

Maddy Dawson, Analyst at Lightning Health shares an overview of the planned reform

England: Clinical commissioning groups are set to be subsumed and dissolved into integrated care systems this year

Research suggests that most ICSs are yet to appoint a procurement lead and their expected structure to govern procurement is still a work in progress

Mental Health Awareness Week 2022

This years theme is loneliness

Poland: Withdraws from contractual purchasing commitments for the Covid-19 vaccine

Eleanor Butler, Senior Consultant takes a closer look at this recent development

Germany: An overview of the healthcare system

In this fact file, Maddy Dawson, Senior Analyst at Lightning Health, takes a look at the healthcare system in Germany: a dual public-private healthcare system

European Joint Clinical Assessment

The EU JCA regulation will apply from 2025 onwards

Germany: The GBA’s planned work programme for 2022

Maddy Dawson, Senior Analyst and Yasmina Zegaoui, Senior Consultant, summarise the key changes that will affect the assessment and pricing of medicines in Germany and the impact these changes will have on the pharmaceutical industry

France: Updated pricing framework for orphan drugs

Yasmina Zegaoui, Senior Consultant at Lightning Health outlines the key changes

60 seconds with Xin Zhao, Senior Consultant

60 seconds with Xin Zhao, Senior Consultant

Team promotions at Lightning Health

A well deserved congratulations to Eleanor and Maddy!

60 seconds with Ciaran Gallagher, Analyst

60 seconds with Ciaran Gallagher, Analyst

World EPA Congress 2022: Round up

Jake James and Eleanor Butler take a look at the key highlights

Germany: Proposed pharmaceutical cost-containment measurers

Maddy Dawson, Analyst at Lightning Health, takes a look at how the draft measures, if implemented, will affect the pharmaceutical industry

European HTA – Key areas for implementation to ensure success in the new EU joint clinical assessments

European HTA – Key areas for implementation to ensure success in the new EU joint clinical assessments

60 seconds with Alan Hutton, Head of Client Engagement and Commercial Development

60 seconds with Alan Hutton, Head of Client Engagement and Commercial Development

Australia: An overview of the healthcare system

In this fact file, Jake James, Analyst at Lightning Health, takes a look at the healthcare system in Australia: a hybrid model that supports cost-effectiveness and cost-minimisation

NICE HTA methods evaluation: Summary of the updated guidance

The updated guidance will come into effect from 1 February 2022 for new evaluations

Supporting Pharmaceutical Innovation in Europe – A round up

Maddy Dawson, Analyst and Eleanor Butler, Consultant at Lightning Health provide a round up of the key topics discussed during the Supporting Pharmaceutical Innovation in Europe webinar

60 seconds with Jake James, Analyst

60 seconds with Jake James, Analyst

Poland: An overview of the healthcare system

The first in a series of fact files reviewing global healthcare systems, Eleanor Butler, Consultant at Lightning Health takes a look at Poland

60 seconds with Stefania Zaccari, Director of Stakeholder Engagement

60 seconds with Stefania Zaccari, Director of Stakeholder Engagement

Lightning Health announces the opening of a new office in New York, US

The expansion demonstrates Lightning Health’s continued commitment to the life sciences sector

Lightning Health’s Market Access Review 2021

A return to the ‘new normal’ – innovations and policies that shaped this year

Modernising the clinical trial: a shift to decentralised trials driven by advances in technology and catalysed by the COVID-19 pandemic

Nancy Cross, Senior Analyst at Lightning Health presents a research poster at ISPOR Europe 2021 on payer awareness and perceptions of decentralised clinical trials. (POSB278)

Challenges and opportunities for digital therapeutics: key requirements to demonstrate value across the EU, England and the US

Nasos Kipentzoglou presents new research at ISPOR Europe 2021 looking at the current processes for the evaluation of digital therapeutics (DTx), to ensure they meet the requirements of healthcare systems and ultimately, benefit patients. (POSB295)

Cross-border collaboration to support pricing and access for high-cost, high-value therapies: a review of initiatives in Europe

Yasmina Zegaoui and Eleanor Butler present recent research at ISPOR Europe reviewing cross-country collaboration models with a focus on health technology assessment

Germany’s coalition government aims to contain healthcare expenditure by reducing the period of free pricing

Details have emerged regarding the new government’s cost-containment plans for the pharmaceutical budget

World Antimicrobial Awareness Week 2021

Lightning Health is proud to support World Antimicrobial Awareness Week

Lightning Health to present three posters at the Virtual ISPOR Europe 2021

Our expert team will present three posters of their recent work and thinking

The introduction of a pan-European HTA: Shaping the landscape for future ATMP launches

An overview of the recent European policy updates and the implications they may have for the launch of ATMPs in Europe

BeNeLuxA initiative supports the reimbursement of Zolgensma® in Belgium, Ireland and the Netherlands

Yasmina Zegaoui, Consultant at Lightning Health, looks at how this managed entry agreement initiative can enable the reimbursement of a much-needed therapy for patients

Team promotions at Lightning Health

A well deserved congratulations to Nancy and Nasos!

ATMP market access: Advanced Therapies Congress & Expo 2021

Yasmina Zegaoui, Senior Consultant and Nasos Kipentzoglou, Senior Analyst at Lightning Health report on some of the key topics from the two-day event

Supporting the life sciences sector

Take a look at how Lightning Health can support your European launch and patient access strategy

We are hiring!

If you want to join our growing team based in the London office, get in touch!

Lightning Health delighted to be presenting three posters at the Virtual ISPOR Europe 2021!

Our expert team will be presenting three posters of our recent work and thinking

Thinking Outside the Box: Sustainable Solutions to Drive Global Patient Access for Advanced Therapy Medicinal Products (ATMPs)

Lightning Health’s thought-leadership perspective on sustainable solutions to drive global patient access for ATMPs

60 seconds with Maddy Dawson, Analyst

60 seconds with Maddy Dawson, Analyst

60 seconds with Yasmina Zegaoui, Senior Consultant

60 seconds with Yasmina Zegaoui, Senior Consultant

Remdesivir for the treatment of COVID-19: A case study on early market access in Europe

Joshua Beddow, Junior Analyst at Lightning Health takes a look at the early market access for remdesivir in Europe

Lightning Health Ltd. announces the change of the company name to Lightning Health Ltd.

Lightning Health Ltd. today announced the change of the company name to Lightning Health Ltd

Virtual cohorts: a method to overcome challenges in developing evidence in rare and complex diseases?

Eleanor Butler,  Consultant at Lightning Health reviews the use of synthetic data and virtual cohorts to mitigate challenges associated with developing evidence in rare and complex diseases

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: International routes

In the last of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes an in-depth look at the international routes; the Access Consortium and Project Orbis

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: Unfettered Access Procedure for marketing authorisations approved in Northern Ireland

In the penultimate of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the Unfettered Access Procedure for marketing authorisations approved in Northern Ireland 

Cancard launch marks an important step to improve attitudes towards medicinal cannabis and help reduce fear for those carrying cannabis-based products for medicinal reasons

Following the launch of Cancard in the UK, Nancy Cross, Analyst at Lightning Health talks about the positive impact the launch may have on individuals carrying medicinal cannabis

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: Decentralised and Mutual Recognition Reliance Procedure

In the fourth of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the Decentralised and Mutual Recognition Reliance Procedure 

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: European Commission (EC) Decision reliance procedure

In the third of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health looks at the European Commission Decision reliance procedure

Managing the symptoms of Parkinson’s Disease with medical cannabis: Exploring the patient perspective

Nancy Cross, Analyst at Lightning Health takes a look at the power of the patient perspective and its importance in increasing the understanding of the potential benefits of medical cannabis

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: rolling review procedure

In the second of our series of posts analysing the new access routes developed in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes a deeper dive into the rolling review procedure

ATMP Market Access: ensuring sustainable patient access to life-changing therapies

How Lightning Health can support you to navigate your access challenges associated with ATMPs

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit: 150-day National Procedure

In the first of a series of articles looking at the mechanisms to obtain marketing authorisation in the UK, Nasos Kipentzoglou, Analyst at Lightning Health takes an in-depth look at the 150-day National Procedure and the possible implications for manufacturers

Retrospective analysis of NICE CAR-T therapy single technology appraisals and identification of strategies to minimise time to patient access

In this article, our colleagues Eleanor Butler and Nancy Cross carry out a retrospective review of the NICE CAR-T therapy single technology appraisals

Guidance for new Marketing Authorisation assessment routes in the UK following Brexit

In the intro of a series of articles, Nasos Kipentzoglou, Analyst at Lightning Health provides a round up of the current mechanisms to obtain marketing authorisation in the UK

The G-BA implements post launch real world evidence generation for Zolgensma®

Nasos Kipentzoglou, Analyst and Eleanor Butler, Consultant at Lightning Health review the recent approach that the G-BA has taken in requiring the mandatory collection of real world evidence for Zolgensma®

NICE rejects gene therapy Zynteglo

Following NICE draft guidance rejecting Zynteglo, Eleanor Butler, Consultant at Lightning Health explores why the beta thalassaemia treatment is not recommend for routine NHS funding

Implications of the UK Rare Diseases Framework for rare disease patients and manufacturers developing new treatments

Nancy Cross, Analyst, and Eleanor Butler, Consultant at Lightning Health review the recently published framework and discuss what this means for stakeholders

60 seconds with Nancy Cross, Analyst

60 seconds with Nancy Cross, Analyst

Happy Festive Season

The team at Lightning Health would like to…

60 seconds with Nasos Kipentzoglou, Analyst

60 seconds with Nasos Kipentzoglou, Analyst

60 seconds with Joshua Beddow, Junior Analyst

60 seconds with Joshua Beddow, Junior Analyst

60 seconds with Alice Best, Platform and Operations Manager

60 seconds with Alice Best, Platform and Operations Manager

60 seconds with Eleanor Butler, Consultant

60 seconds with Eleanor Butler, Consultant

Why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare

This week our colleagues Eleanor Butler and Marina Kousta attended an ISPOR webinar, read their blog.

60 seconds with Marina Kousta, Analyst

60 seconds with Marina Kousta, Analyst

60 seconds with Stuart Hurst, Executive Advisor (Launch Excellence)

60 seconds with Stuart Hurst, Executive Advisor (Launch Excellence)

60 seconds with Andrew Satherley, Joint Managing Director

60 seconds with Andrew Satherley, Joint Managing Director

60 seconds with James Whitehouse, Joint Managing Director

60 seconds with James Whitehouse, Joint Managing Director

UK parliament steps up plans for medicines access post Brexit

The UK parliament has published contingency legislation to ensure continuity of medicines access and clinical trials in the event of a no deal Brexit.

Dr Frances Macdonald joins the Lightning Health network

The Lightning Health team is delighted to announce Dr Frances Macdonald is joining the network as an executive advisor for European HTA.

The NHS England long term plan

NHS England has published its long-awaited long-term NHS plan, setting out the strategic objectives for the NHS over the next 10 years.